Woburn, MA,  February 25th, 2020  Novatein Biosciences Inc launched antigen and antibodies products for the 2019-nCoV/COVIS-19/SARS-COV2 research.

Reagents providers Novatein Biosciences have recently announced that they have added antigen and antibodies for the 2019-nCoV/COVIS-19/SARS-COV2 to the company’s comprehensive catalogue. The new 2019-nCoV/COVIS-19/SARS-COV2 antigens and antibodies, as well as assay kit will be a great help for the researchers and medical professionals to develop diagnostics, vaccine and drugs around the world.

Novatein Biosciences, a biological reagents provider located in the greater Boston area, started offering antigen and antibodies (coming soon) for the 2019-nCoV/COVIS-19/SARS-COV2 to the researchers around the world. The antigens and antibodies, as well as assay kit will be a great help for the researchers and medical professionals to develop diagnostics, vaccine and drugs around the world. The 2019-nCoV/COVIS-19/SARS-COV2 antigen and antibodies are:

Recombinant 2019-nCov Nucleocapsid Protein
Recombinant 2019-nCoV Spike(S1 Subunit)_His Protein
Recombinant 2019-nCov Nucleocapsid Protein
Recombinant 2019-nCoV Spike(RBD)/hFc Protein
Human Angiotensin I Converting Enzyme 2 ACE2 ELISA Kit
Recombinant Human ACE2(Met1-Ser740)/hFc Protein

Novatein Biosciences has been provide high quality proteins, antibodies, and assay kits for biomedical research communities. At this public health crisis caused by coronavirus, Novatein Biosciences hopes to work together with biomedicine professionals to fight for human health.

Background

The outbreak of a novel betacoronavirus (2019-nCov) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for urgently needed vaccines, therapeutic antibodies, and diagnostics.

The novel coronavirus 2019-nCoV has recently emerged as a human pathogen in the city of Wuhan in China’s Hubei province, causing fever, severe respiratory illness and pneumonia. According to the World Health Organization on February 10th, 2020, there have been over 40,000 confirmed cases globally, leading to at least 900 deaths. The new pathogen was rapidly shown to be a novel member of the betacoronavirus genus that is closely related to several bat coronaviruses as well as severe acute respiratory syndrome coronavirus (SARS-CoV). Compared to SARS-CoV, 2019-nCoV appears to be more readily transmitted from human-to-human, spreading to multiple continents and leading to the WHO declaration of a Public Health Emergency of International Concern (PHEIC).

2019-nCoV/COVID/SARS-CoV2 makes use of a densely glycosylated, homotrimeric class I fusion spike (S) protein to gain entry into host cells. The S protein exists in a metastable prefusion conformation that undergoes a dramatic structural rearrangement to fuse the viral membrane with the host cell membrane. This process is triggered by binding of the S1 subunit to a host-cell receptor ACE2, which destabilizes the prefusion trimer, resulting in shedding of the S1 subunit and transition of the S2 subunit to a highly stable postfusion conformation. In order to engage a host-cell receptor, the receptor-binding domain (RBD) of S1 undergoes hinge-like conformational movements that transiently hide or expose the determinants of receptor binding. These two states are referred to as the “down” conformation and the “up” conformation, where “down” corresponds to the receptor-inaccessible state and “up” corresponds to the receptor-accessible state, which is thought to be less stable. Due to the indispensable function of the S protein it represents a vulnerable target for antibody-mediated neutralization, and characterization of the prefusion S structure would provide atomic-level information to guide vaccine design and development.

As in other coronaviruses, nucleocapsid (N) is one of the most crucial structural components of the 2019nCoV, or COVID/NCP. Hence major attention has been focused on characterization of this protein. Independent studies conducted by several laboratories have elucidated significant insight into the primary function of this protein, which is to encapsidate the viral genome. The COVID N protein share high homology with the SARS-Cov’s N protein. Therefore, is has very similar function and can have similar applications in the aspect of diagnostic and vaccination.